Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Sep 10

PMID 34502442

Citations 6

Authors

Haruka Tsuchiya

Keishi Fujio

Affiliations

Soon will be listed here.

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease characterized by destructive synovitis. It is significantly associated with disability, impaired quality of life, and premature mortality. Recently, the development of biological agents (including tumor necrosis factor-α and interleukin-6 receptor inhibitors) and Janus kinase inhibitors have advanced the treatment of RA; however, it is still difficult to predict which drug will be effective for each patient. To break away from the current therapeutic approaches that could be described as a "lottery," there is an urgent need to establish biomarkers that stratify patients in terms of expected therapeutic responsiveness. This review deals with recent progress from multi-faceted analyses of the synovial tissue in RA, which is now bringing new insights into diverse features at both the cellular and molecular levels and their potential links with particular clinical phenotypes.

Citing Articles

IGF2BP3 regulates the expression of RRM2 and promotes the progression of rheumatoid arthritis via RRM2/Akt/MMP-9 pathway.

Ban Z, Li Z, Xing S, Ye Y PLoS One. 2024; 19(5):e0303593.

PMID: 38820515 PMC: 11142689. DOI: 10.1371/journal.pone.0303593.

Age, Sex, Metabolic and Pharmacologic Factors May Predict Nonresponse Status to Rheumatoid Arthritis Therapies.

Bordean L, Chis M, Cimpean A, Barb A, Cosma A, Pasca Fenesan M In Vivo. 2023; 37(5):2387-2401.

PMID: 37652478 PMC: 10500531. DOI: 10.21873/invivo.13344.

The Pathogenesis of Rheumatoid Arthritis Breakthroughs in Molecular Mechanisms 1 and 2.

Nanke Y Int J Mol Sci. 2023; 24(13).

PMID: 37446237 PMC: 10341906. DOI: 10.3390/ijms241311060.

Tailored therapeutic decision of rheumatoid arthritis using proteomic strategies: how to start and when to stop?.

Chen S, Yeh F, Chen C, Chang H Clin Proteomics. 2023; 20(1):22.

PMID: 37301840 PMC: 10257292. DOI: 10.1186/s12014-023-09411-2.

Levelling the playing field of RMD research across Europe to address patients' needs: the emerging EULAR Research Centre.

Reuter K, Haupt C, Molto A, Cope A, van Vollenhoven R, Elewaut D RMD Open. 2022; 8(2).

PMID: 35714997 PMC: 9207999. DOI: 10.1136/rmdopen-2022-002456.

References

Humby F, Durez P, Buch M, Lewis M, Rizvi H, Rivellese F . Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021; 397(10271):305-317. PMC: 7829614. DOI: 10.1016/S0140-6736(20)32341-2. View

Iannone F, Courvoisier D, Gottenberg J, Hernandez M, Lie E, Canhao H . Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). Clin Rheumatol. 2016; 36(4):773-779. DOI: 10.1007/s10067-016-3505-5. View

Smolen J, Aletaha D, Barton A, Burmester G, Emery P, Firestein G . Rheumatoid arthritis. Nat Rev Dis Primers. 2018; 4:18001. DOI: 10.1038/nrdp.2018.1. View

Aterido A, Canete J, Tornero J, Blanco F, Fernandez-Gutierrez B, Perez C . A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis. Front Immunol. 2019; 10:1459. PMC: 6614444. DOI: 10.3389/fimmu.2019.01459. View

Wu X, Sheng X, Sheng R, Lu H, Xu H . Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis. Front Med. 2019; 13(4):411-419. DOI: 10.1007/s11684-018-0659-3. View

Maksymowych W, Marotta A . 14-3-3η: a novel biomarker platform for rheumatoid arthritis. Clin Exp Rheumatol. 2014; 32(5 Suppl 85):S-35-9. View

Acosta-Herrera M, Gonzalez-Serna D, Martin J . The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis. J Clin Med. 2019; 8(6). PMC: 6617101. DOI: 10.3390/jcm8060826. View

Mizoguchi F, Slowikowski K, Wei K, Marshall J, Rao D, Chang S . Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun. 2018; 9(1):789. PMC: 5824882. DOI: 10.1038/s41467-018-02892-y. View

Mariette X, Alten R, Nusslein H, Galeazzi M, Lorenz H, Cantagrel A . The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. Joint Bone Spine. 2017; 84(5):571-576. DOI: 10.1016/j.jbspin.2016.10.011. View

10.

Potter C, Hyrich K, Tracey A, Lunt M, Plant D, Symmons D . Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2008; 68(1):69-74. PMC: 2596303. DOI: 10.1136/ard.2007.084715. View

11.

Klaasen R, Wijbrandts C, Gerlag D, Tak P . Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011; 63(2):359-64. DOI: 10.1002/art.30136. View

12.

Orr C, Vieira-Sousa E, Boyle D, Buch M, Buckley C, Canete J . Synovial tissue research: a state-of-the-art review. Nat Rev Rheumatol. 2017; 13(8):463-475. DOI: 10.1038/nrrheum.2017.115. View

13.

Zhang F, Wei K, Slowikowski K, Fonseka C, Rao D, Kelly S . Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019; 20(7):928-942. PMC: 6602051. DOI: 10.1038/s41590-019-0378-1. View

14.

DAgostino M, Alten R, Mysler E, Le Bars M, Ye J, Murthy B . Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. Clin Rheumatol. 2017; 36(12):2655-2665. PMC: 5681604. DOI: 10.1007/s10067-017-3788-1. View

15.

Liu Y, Hazlewood G, Kaplan G, Eksteen B, Barnabe C . Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2016; 69(2):157-165. DOI: 10.1002/acr.22932. View

16.

Mateos J, Lourido L, Fernandez-Puente P, Calamia V, Fernandez-Lopez C, Oreiro N . Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI TOF/TOF. J Proteomics. 2012; 75(10):2869-78. DOI: 10.1016/j.jprot.2011.12.042. View

17.

Quax R, Koper J, Huisman A, Weel A, Hazes J, Lamberts S . Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis. Rheumatol Int. 2015; 35(8):1325-33. PMC: 4473091. DOI: 10.1007/s00296-015-3235-z. View

18.

Vordenbaumen S, Joosten L, Friemann J, Schneider M, Ostendorf B . Utility of synovial biopsy. Arthritis Res Ther. 2009; 11(6):256. PMC: 3003519. DOI: 10.1186/ar2847. View

19.

Lliso-Ribera G, Humby F, Lewis M, Nerviani A, Mauro D, Rivellese F . Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis.... Ann Rheum Dis. 2019; 78(12):1642-1652. PMC: 6900253. DOI: 10.1136/annrheumdis-2019-215751. View

20.

Wampler Muskardin T, Vashisht P, Dorschner J, Jensen M, Chrabot B, Kern M . Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. Ann Rheum Dis. 2015; 75(10):1757-62. PMC: 4860184. DOI: 10.1136/annrheumdis-2015-208001. View